Pharma Leaders Unite to Promote Ready-to-Use Packaging Solutions, Enhancing Safety and Efficiency

Pharma Leaders Unite to Promote Ready-to-Use Packaging Solutions, Enhancing Safety and Efficiency

(IN BRIEF) SCHOTT Pharma, Gerresheimer, and Stevanato Group have formed the “Alliance for RTU” to promote the adoption of ready-to-use (RTU) vials and cartridges within the pharmaceutical industry. This strategic alliance aims to streamline pharmaceutical manufacturing, improve operational efficiency, and enhance patient safety through high-quality sterile packaging. By transitioning from traditional bulk packaging to RTU solutions, pharmaceutical companies and contract manufacturers can reduce operational risks, improve flexibility, lower costs, and meet regulatory standards like EU GMP Annex 1. The alliance also seeks to create an open platform for industry players to better understand RTU technology and assess the benefits of adopting it. The alliance will be officially presented at the CPhI in Milan on October 8.

(PRESS RELEASE) MAINZ, 27-Sep-2024 — /EuropaWire/ — SCHOTT Pharma, Gerresheimer, and Stevanato Group have officially joined forces to form the “Alliance for RTU” (Ready-to-Use), aimed at accelerating the adoption of ready-to-use vials and cartridges in the pharmaceutical industry. The collaboration intends to promote operational efficiency in drug manufacturing while ensuring patient safety through high-quality sterile primary packaging. By transitioning from traditional bulk packaging to an RTU setup, pharmaceutical companies and contract manufacturers can reduce risks, increase flexibility, and streamline production processes, ultimately lowering costs and contamination risks. This shift is aligned with regulatory requirements, including EU GMP Annex 1 compliance.

In addition to offering high-quality products that minimize the chances of breakage and glass particle release, the alliance will serve as an expert platform, providing industry players with insights into the benefits of RTU solutions and aiding in decision-making processes regarding investments in advanced filling systems. Leaders from SCHOTT Pharma, Gerresheimer, and Stevanato Group emphasize the importance of RTU technology in modern pharmaceutical production, underscoring its role in enhancing the safety and efficiency of medication delivery. The Alliance for RTU will be introduced at the CPhI in Milan on October 8.

For more details, visit www.alliance-for-rtu.com

About SCHOTT Pharma

Human health matters. That is why SCHOTT Pharma designs solutions grounded in science to ensure that medications are safe and easy to use for people around the world. The portfolio comprises drug containment solutions and delivery systems for injectable drugs ranging from prefillable glass and polymer syringes to cartridges, vials, and ampoules. Every day, a team of over 4,600 people from over 60 nations works at SCHOTT Pharma to contribute to global healthcare. The company is represented in all main pharmaceutical hubs with 16 manufacturing sites in Europe, North and South America, and Asia. With over 1,000 patents and technologies developed in-house and a state-of-the-art R&D center in Switzerland, the company is focused on developing innovations for the future. SCHOTT Pharma AG & Co. KGaA is headquartered in Mainz, Germany and listed on the Frankfurt Stock Exchange as part of the MDAX. It is part of SCHOTT AG, which is owned by the Carl Zeiss Foundation. In light of this spirit, SCHOTT Pharma is committed to sustainable development for society and the environment and has the strategic goal of becoming climate-neutral by 2030. Currently, SCHOTT Pharma has over 1,800 customers including the top 30 leading pharma manufacturers for injectable drugs and generated revenue of EUR 899 million in the fiscal year 2023. Further information at www.schott-pharma.com.

About Gerresheimer

Gerresheimer is an innovative systems and solutions provider and a global partner to the pharma, biotech, and cosmetics industries. The company offers a comprehensive portfolio of pharmaceutical containment solutions, drug delivery systems and medical devices as well as solutions for the health industry. The product range includes digital solutions for therapy support, medication pumps, syringes, pens, auto-injectors and inhalers as well as vials, ampoules, tablet containers, infusion, dropper and syrup bottles, and more. With 35 production sites in 16 countries in Europe, America and Asia, Gerresheimer has a global presence and produces locally for regional markets. With around 12,000 employees, the company generated revenues of around €2bn in 2023. Gerresheimer AG is listed in the MDAX on the Frankfurt Stock Exchange (ISIN: DE000A0LD6E6). www.gerresheimer.com

About Stevanato Group

Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. The Group delivers an integrated, end-to-end portfolio of products, processes and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages. Stevanato Group’s core capabilities in scientific research and development, its commitment to technical innovation and its engineering excellence are central to its ability to offer value added solutions to clients. To learn more, visit: stevanatogroup.com.

Media Contact:

Joana Kornblum
Manager Corporate Communications

SOURCE: SCHOTT Pharma